CALC

CALCIMEDICA INC (CALC) | Rumor.io

CALCIMEDICA

CALC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,044

Bullish sentiment (50-day avg)72%

Price to earnings ratio0.3

Market capitalization11.5M

Earnings per share-6.85

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-29.6M

Social

What share of all stock conversation is about CALC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 31

CalciMedica, Inc. has announced a reverse stock split and CUSIP number change, which may have contributed to a pullback, but could potentially recover to $0.80-$0.90 per share post-split.
Short interest in $CALC has doubled since last week, and the stock is still not heavily shorted.
The stock has seen an increase in volume, and some traders are predicting a run after a dip to $1.75 or lower.

Generated by AI

Sentiment

Of the messages about CALC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.45% -34.55	75% +4.46	80.89% -8.42
Bearish	—	54.55% +34.55	25% -4.46	19.11% +8.42

Bullish· Jun 24

CalciMedica, Inc. (CALC) is seeing significant investment from its management team, which is a positive sign.
The company's recent $50 million offering, with warrants at $0.80 and $1, could lead to a substantial increase in its stock price.
CALC has the potential to reach $5.30 and fill the gap, with some analysts predicting it could take off once it finds its legs.

Bearish· Jun 24

The private placement of up to $49 million may be causing investors to sell and leave money on the table, potentially leading to a price drop.
The company's pulmonary hypertension program received a favorable FDA review, but the stock is still pulling back from early highs, with massive volume relative to the float.
The news of the private placement and FDA review may be seen as "good news" for bears, potentially leading to a continuation of the stock's downward trend.

Generated by AI

Topics

Of the messages about CALC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	100%	10.86%
Announcements	—	0%	0%	57.32%
Analysts	—	0%	0%	16.67%
Controversies	—	0%	0%	0.76%
Earnings	—	0%	0%	0.25%
Macro	—	0%	0%	14.14%

Jun 28

The asset is in a breakout formation, with a potential target above $5.87.
The 50 EMA and 200 EMA are providing support, with the latter being a key level to watch.
A strong bounce is possible if the asset closes near resistance, with potential continuation into the next day.

Generated by AI

Community

Of the messages about CALC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	85.71%	76.56%	31.61%
Newcomers	0%	14.29%	23.44%	68.39%

Regulars· Aug 27

The recent 1:5 reverse stock split (R/S) is not expected to have a significant impact on the company's valuation, with one participant stating it means nothing and another noting it will only affect retail investors' desire to sell.
Several participants are optimistic about the company's potential for a big pharma partnership for its Auxuora AP product, with one suggesting this could include an upfront payment of around $50M and milestone payments for a successful Phase 3 trial and commercialization.
The company's share price is expected to find support at around $2 or lower, with one participant suggesting this could happen as soon as the new price is traded.

Newcomers· Jan 28

CalciMedica's stock faces a significant hit as Phase 2 AKI trial is halted for safety, overshadowing other program optimism.
The company is discontinuing a key trial for its lead drug candidate, which triggered a massive sell-off and plunged the stock 76% today.
The halt in trading for $CALC at 6:55 AM pending news may signal a major pending announcement, indicating a potential momentum shift or volatility.

Generated by AI

News

CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized

Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk

Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.

27d agoThe Globe and Mail

CalciMedica Announces One-for-Five Reverse Stock Split

Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about CALC also mention

#	Name	Attention
1	Seer, Inc. Class A Common StockSEER	0%0
2	Amesite Inc.AMST	0%new
3	Multi Ways Holdings Ltd.MWG	0%0
4	Cuentas Inc.CUEN	0%+0
5	Chemomab Therapeutics Ltd. American Depositary SharesCMMB	0%0
6	Galecto Inc.GLTO	0%0
7	RLX Technology Inc. ADRRLX	0%0
8	Aspen Group Inc.ASPU	0%new
9	Collplant Biotechnologies LtdCLGN	0%0
10	Rezolute Inc.RZLT	0%+0

CALCIMEDICA INC

Healthcare
Biotechnology

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.

Website

Location

505 Coast Boulevard South

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about CALC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 31

CalciMedica, Inc. has announced a reverse stock split and CUSIP number change, which may have contributed to a pullback, but could potentially recover to $0.80-$0.90 per share post-split.
Short interest in $CALC has doubled since last week, and the stock is still not heavily shorted.
The stock has seen an increase in volume, and some traders are predicting a run after a dip to $1.75 or lower.

Generated by AI

Sentiment

Of the messages about CALC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.45% -34.55	75% +4.46	80.89% -8.42
Bearish	—	54.55% +34.55	25% -4.46	19.11% +8.42

Bullish· Jun 24

CalciMedica, Inc. (CALC) is seeing significant investment from its management team, which is a positive sign.
The company's recent $50 million offering, with warrants at $0.80 and $1, could lead to a substantial increase in its stock price.
CALC has the potential to reach $5.30 and fill the gap, with some analysts predicting it could take off once it finds its legs.

Bearish· Jun 24

The private placement of up to $49 million may be causing investors to sell and leave money on the table, potentially leading to a price drop.
The company's pulmonary hypertension program received a favorable FDA review, but the stock is still pulling back from early highs, with massive volume relative to the float.
The news of the private placement and FDA review may be seen as "good news" for bears, potentially leading to a continuation of the stock's downward trend.

Generated by AI

Topics

Of the messages about CALC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	100%	10.86%
Announcements	—	0%	0%	57.32%
Analysts	—	0%	0%	16.67%
Controversies	—	0%	0%	0.76%
Earnings	—	0%	0%	0.25%
Macro	—	0%	0%	14.14%

Jun 28

The asset is in a breakout formation, with a potential target above $5.87.
The 50 EMA and 200 EMA are providing support, with the latter being a key level to watch.
A strong bounce is possible if the asset closes near resistance, with potential continuation into the next day.

Generated by AI

Community

Of the messages about CALC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	85.71%	76.56%	31.61%
Newcomers	0%	14.29%	23.44%	68.39%

Regulars· Aug 27

The recent 1:5 reverse stock split (R/S) is not expected to have a significant impact on the company's valuation, with one participant stating it means nothing and another noting it will only affect retail investors' desire to sell.
Several participants are optimistic about the company's potential for a big pharma partnership for its Auxuora AP product, with one suggesting this could include an upfront payment of around $50M and milestone payments for a successful Phase 3 trial and commercialization.
The company's share price is expected to find support at around $2 or lower, with one participant suggesting this could happen as soon as the new price is traded.

Newcomers· Jan 28

CalciMedica's stock faces a significant hit as Phase 2 AKI trial is halted for safety, overshadowing other program optimism.
The company is discontinuing a key trial for its lead drug candidate, which triggered a massive sell-off and plunged the stock 76% today.
The halt in trading for $CALC at 6:55 AM pending news may signal a major pending announcement, indicating a potential momentum shift or volatility.

Generated by AI

CALCIMEDICA

Social

Aug 31

Bullish· Jun 24

Bearish· Jun 24

Jun 28

Regulars· Aug 27

Newcomers· Jan 28

CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized

CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk

CalciMedica Announces One-for-Five Reverse Stock Split

CalciMedica executes 1-for-5 reverse stock split

Guggenheim initiates CalciMedica stock with buy rating on drug potential

Guggenheim initiates CalciMedica stock coverage with buy rating

Also Discussed

CALCIMEDICA INC

Company Information

Location

CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized

CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk

CalciMedica Announces One-for-Five Reverse Stock Split

CalciMedica executes 1-for-5 reverse stock split

Guggenheim initiates CalciMedica stock with buy rating on drug potential

Guggenheim initiates CalciMedica stock coverage with buy rating

Also Discussed

Social

Aug 31

Bullish· Jun 24

Bearish· Jun 24

Jun 28

Regulars· Aug 27

Newcomers· Jan 28